title: Comparison of the quantitative performances and measurement uncertainty estimates obtained during method validation versus routine applications of a novel hydrophilic interaction chromatography method for the determination of cidofovir in human plasma.
abstract: Method validation is essential to ensure that an analytical method is fit for its intended purpose. Additionally, it is advisable to estimate measurement uncertainty in order to allow a correct interpretation of the results generated by analytical methods. Measurement uncertainty can be efficiently estimated during method validation as a top-down approach. However, method validation predictions of the quantitative performances of the assay and estimations of measurement uncertainty may be far away from the real performances obtained during the routine application of this assay. In this work, the predictions of the quantitative performances and measurement uncertainty estimations obtained from a method validation are compared to those obtained during routine applications of a bioanalytical method. For that purpose, a new hydrophilic interaction chromatography (HILIC) method was used. This method was developed for the determination of cidofovir, an antiviral drug, in human plasma. Cidofovir (CDV) is a highly polar molecule presenting three ionizable functions. Therefore, it is an interesting candidate for determination by HILIC mode. CDV is an acyclic cytidine monophosphate analog that has a broad antiviral spectrum and is currently undergoing evaluation in clinical trials as a topical agent for treatment of papillomavirus infections. The analytical conditions were optimized by means of design of experiments approach in order to obtain robust analytical conditions. These ones were absolutely necessary to enable the comparisons mentioned above. After a sample clean-up by means of solid phase extraction, the chromatographic analysis was performed on bare silica stationary phase using a mixture of acetonitrile-ammonium hydrogen carbonate (pH 7.0; 20mM) (72:28, v/v) as mobile phase. This newly developed bioanalytical method was then fully validated according to FDA (Food and Drug Administration) requirements using a total error approach that guaranteed that each future result will fall within acceptance limits of ±30% with a probability of 95% over a concentration range of 92.7-1020ng/mL. A routine application of the cidofovir determination in two pre-clinical trials demonstrated that the prediction made during the pre-study validation was consistent by retrospective analysis of the quality control (QC) samples. Finally, comparison of the measurement uncertainty estimations calculated from the method validation with those obtained from the routine application of the method was performed, stressing that the estimations obtained during method validation underestimated those obtained from routine applications and that the magnitude of this underestimation was function of the cidofovir concentration. Finally, this new HILIC method is reliable, easily applicable to routine analysis and transposable at low cost in other laboratories.
authors.affiliation: Laboratory of Analytical Chemistry, CIRM, Institute of Pharmacy, University of Liège, CHU, B36, Tour 4, Avenue de l'Hôpital 1, B-4000 Liège, Belgium. F.Lecomte@ulg.ac.be
authors.forename: F
authors.initials: F
authors.lastname: Lecomte
authors.forename: C
authors.initials: C
authors.lastname: Hubert
authors.forename: S
authors.initials: S
authors.lastname: Demarche
authors.forename: C
authors.initials: C
authors.lastname: De Bleye
authors.forename: A
authors.initials: A
authors.lastname: Dispas
authors.forename: M
authors.initials: M
authors.lastname: Jost
authors.forename: F
authors.initials: F
authors.lastname: Frankenne
authors.forename: A
authors.initials: A
authors.lastname: Ceccato
authors.forename: E
authors.initials: E
authors.lastname: Rozet
authors.forename: Ph
authors.initials: P
authors.lastname: Hubert
mesh_terms: D000998:Antiviral Agents / Q000097:blood*; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000097:blood; D006801:Humans; D063065:Organophosphonates / Q000097:blood*; D012015:Reference Standards; D035501:Uncertainty
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir